At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓History of treated well-differentiated epithelial thyroid carcinoma (papillary, follicular, or Hurthle cell) with total or near total thyroidectomy and postoperative radioiodine ablation or imaging showing ablation unnecessary
- ✓Serum thyroglobulin ≥10 ng/mL without interfering autoantibodies
- ✓No qualifying radioiodine whole body scan findings sufficient to localize disease despite elevated thyroglobulin
- ✕Diabetes mellitus
- ✕Claustrophobia, inability to lay supine, or other factors preventing cooperation with scanning procedures
- ✕Thyroid hormone withdrawal or rTSH administration within the preceding month
- ✕Circulating thyroglobulin autoantibodies interfering with serum thyroglobulin measurement
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-differentiated Epithelial Thyroid Cancer
In Brief
A Phase 2 clinical trial evaluating Euthyroid Group for Thyroid Cancer. Completed, enrolled 63 participants across 3 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine \[for patients with previously treated well-differentiated thyroid cancer and evidence of residual disease based on serum thyroglobulin (Tg) level\] whether positron emission tomography-computed tomography (PET-CT) fusion scanning performed after recombinant thyroid-stimulating hormone (TSH) (rTSH, thyrotropin alfa for injection) will be more sensitive for the detection of disease sites than PET-CT scanning without rTSH. The study will also determine if this information will significantly alter the therapeutic approach in some patients.
Study Details
Timeline
Interventions
Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.